Oncology

Institute of Cancer Research
#Oncology #Oncolytic virus #Ovarian cancer #Phase II trial

Oncolytic immunotherapy could offer new option in ovarian cancer

Biotechnology firm Theolytics has been awarded €8 million research funding through the Horizon Europe programme, to support expansion of the OCTOPOD‑IV Phase IIa trial in platinum‑resistant ovarian cancer.  The trial will evaluate THEO‑260 — a next‑generation oncolytic immunotherapy designed… Read More

#Cancer Research #News

Medical professional examining mammogram
#Breast cancer #Oncology #Phase III trial #Roche

Roche breast cancer study fails to meet primary objective

Roche has announced that its Phase III persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed.  The trial assessed giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal… Read More

#Cancer Research #News

Modern medical science laboratory
#Cancer research #Oncology #Paediatrics

C-Further announces oncology therapeutic programmes 

C-Further has unveiled its first early-stage therapeutic programmes dedicated to paediatric oncology indications.  The international consortium is set to advance CF-012 for the treatment of Ewing sarcoma, in collaboration with investigators at UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute and Mass General Brigham, and has also partnered with MiNK Therapeutics to… Read More

#Cancer Research #News

#Ascendis Pharma #BioIndustry Association #Cancer therapy #CHMP #Clinical trial #Diversity #European Medicines Agency #FDA #Gene therapy #Oncology #Paediatrics #Rare disease #uniQure #University of Queensland #Women in STEM

DDW Highlights: 10 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, figures showed the number of women in biotech leadership has stalled. Elsewhere, could… Read More

#Podcasts

European Commission
#European Commission #Incyte #Monoclonal antibodies #Oncology

European Commission approves retifanlimab for anal cancer

The European Commission (EC) has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).  Rretifanlimab is the first systemic treatment for adult patients with advanced SCAC in Europe. … Read More

#News #Regulatory

Doctor showing a model of the prostate
#European Commission #Johnson & Johnson #Oncology #Prostate cancer

Dual action prostate cancer drug gets expanded indication in EU

The European Commission has approved an indication extension for Akeega (niraparib and abiraterone acetate dual action tablet) with prednisone or prednisolone (AAP) in combination with androgen deprivation therapy (ADT).  The regimen is now also approved for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and BRCA1/2 mutations (germline… Read More

#News #Regulatory

#Celyn Therapeutics #Kairos Pharma #Lung cancer #Mergers and acquisitions #Oncology

Kairos acquires AI‑designed pan‑EGFR inhibitor from Celyn

Kairos Pharma has entered into binding terms to acquire CL-273, an investigational, reversible, wild-type-sparing pan‑EGFR small‑molecule inhibitor, from Celyn Therapeutics.  CL-273 was discovered using a proprietary AI-driven drug discovery platform. It targets the resistant mutations that develop when using EGFR tyrosine kinase inhibitors, thereby reversing resistance.   It is specifically engineered… Read More

#Business & Investment #News

FDA headquarters
#FDA #Haematology #Oncology #Pentixapharm #Radiopharmaceuticals

FDA approves Pentixapharm’s dual theranostic INDs

The US Food and Drug Administration (FDA) has approved a clinical study of Pentixapharm’s CXCR4-targeted theranostic programme in haemato-oncology, following a 30-day safety review of two Investigational New Drug (IND) applications.  The two IND submissions support the single PENTHERA Phase I/II protocol, which evaluates the combined use of PentixaFor imaging… Read More

#News #Regulatory

Tumour microenvironment
#Insilico Medicine #KRAS #Oncology #Solid tumours

Insilico Medicine nominates pan-KRAS preclinical candidate

Insilico Medicine has nominated ISM6166 as a preclinical candidate, a potent, oral pan-KRAS inhibitor designed to treat a broad spectrum of solid tumours.  Among the Ras family of oncogenes, KRAS is one of the most frequently altered drivers in human cancer, playing a key role in regulating… Read More

#Cancer Research #News

Blood cancer
#Myeloma #Oncology #Phase II trial #Starton Therapeutics

STAR-LLD seeks to replace standard care for blood cancers

Starton Therapeutics announced it has dosed the first patient in its Phase IIa study evaluating STAR-LLD for the treatment of relapsed/refractory multiple myeloma (RRMM).  STAR-LLD is a continuous delivery lenalidomide (LLD) in development seeking to expand and replace the standard-of-care for the most common blood cancers, multiple… Read More

#Cancer Research #News

#Animal models #Oncology #Osteosarcoma #Preclinical investigations

Comparative oncology in osteosarcoma: Leveraging canine disease to drive discovery

How can we leverage canine osteosarcoma to validate biomarkers and accelerate the pathway to new therapies? Integration of comparative biology, specifically the study of naturally occurring cancers in companion animals (primarily dogs) known as comparative oncology, over the last three decades has significantly transformed cancer research and translational medicine. The… Read More

#Exclusive Content

Ovarian cancer cells
#Clinical trial #Oncology #Ovarian cancer

Ovarian cancer treatment could prevent peritoneal recurrence 

A new treatment for ovarian cancer could prevent peritoneal recurrence, data suggests.  Biotech company Oncoinvent is set to present results from the Phase I study of Radspherin after cytoreductive surgery in patients with platinums ensitivesensitive epithelial ovarian cancer. According to data released in advance, nine of 10 patients treated on the highest dose remained free… Read More

#Cancer Research #News

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK

DDW Highlights: 17 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers made a key discovery into cancer survival. Elsewhere, a global research effort… Read More

#Podcasts

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK #United States

This week in Drug Discovery (9 – 13 February) 

News round-up for 9 – 13 February by Bruno Quinney, Content Team at DDW.  This week in DDW, researchers have made a key discovery into cancer survival. Elsewhere, a global research effort into kidney disease is underway.  The top stories:    Researchers identify RNA linked to cancer… Read More

#News